Logo
x

Search category

Subscribe Now

All Posts by Date

Kala Pharmaceuticals Reports the US FDA’s Acceptance of IND Application of KPI-012 for Persistent Corneal Epithelial Defect

Kala Pharmaceuticals Reports the US FDA’s Acceptance of IND Application of KPI-012 for Persistent Corneal Epithelial Defect

  • December 28, 2022
Insights+: EMA Marketing Authorization of New Drugs in November 2022

Insights+: EMA Marketing Authorization of New Drugs in November 2022

  • December 28, 2022
AstraZeneca’s Calquence (acalabrutinib) Receives the MHLW’s Approval for Treatment-Naïve Chronic Lymphocytic Leukaemia

AstraZeneca’s Calquence (acalabrutinib) Receives the MHLW’s Approval for Treatment-Naïve Chronic Lymphocytic Leukaemia

  • December 28, 2022
Chong Kun Dang Pharmaceutical Reports P-III Trials of CKD-701 (biosimilar, ranibizumab) for the Treatment of Neovascular Age-Related Macular Degeneration

Chong Kun Dang Pharmaceutical Reports P-III Trials of CKD-701 (biosimilar, ranibizumab) for the Treatment of Neovascular Age-Relat...

  • December 28, 2022
SpringWorks Reports the Completion of NDA Submission to the US FDA for Nirogacestat to Treat Desmoid Tumors

SpringWorks Reports the Completion of NDA Submission to the US FDA for Nirogacestat to Treat Desmoid Tumors

  • December 28, 2022
Polarean’s Xenoview (xenon Xe 129 hyperpolarized) Receives the US FDA’s Approval for Lung Ventilation

Polarean’s Xenoview (xenon Xe 129 hyperpolarized) Receives the US FDA’s Approval for Lung Ventilation

  • December 28, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.